Search Results

Aileron Therapeutics, Inc. announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024.

Aileron Therapeutics, Inc. announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Aileron Therapeutics, Inc. today announced that current President and Chief Operating Officer, Brian Windsor, Ph.D., has been appointed President and Chief Executive Officer (CEO) and will join the Board of Directors, effective March 11, 2024.

Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. (“Lung Tx”).

Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Aileron Therapeutics, Inc. announced the closing of its previously announced underwritten registered direct offering priced at-the-market under Nasdaq rules of 4,273,505 shares of its common stock and accompanying warrants to purchase an aggregate of 4,273,505 shares of common stock.

Aileron Therapeutics, Inc. announced that it will host a virtual key opinion leader event titled, “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” on Thursday, February 15, 2024, from 4:30 to 5:30 p.m. ET.

Aileron Therapeutics, Inc. today announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating the safety and tolerability of inhaled LTI-03 in patients diagnosed with idiopathic pulmonary fibrosis (IPF).

Aileron Therapeutics, Inc. will host a virtual key opinion leader event from 4:30 to 5:30 p.m. ET titled “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” featuring pulmonary care experts Fernando J. Martinez, M.D., M.S. from Weill Cornell Medicine; Tejaswini Kulkarni, M.D., M.P.H. from University of Alabama at Birmingham Medicine; and Andreas Günther, M.D. from Agaplesion Evang.